Our CEO Malcolm Hebblewhite recently chatted with Theresa “Sam” Houghton of The Modern Health Nerd podcast about how Atmo is shining a light on the mysteries of the human gut, and what that could mean for the millions of people who suffer from gut disorders like IBS and IBD.
Listen to the discussion below or search for “The Modern Health Nerd” on Apple Podcasts, Overcast or Spotify.
Atmo Biosciences has been awarded a $620,000 Australian Government grant through the BioMedTech Horizons (BMTH) program.
Atmo Biosciences has raised a further A$2.5 million in an oversubscribed funding round, supplementing an initial seed raise in March 2019.
Seed Health, a microbial sciences company, is partnering with Atmo Biosciences to use its ingestible gas-sensing capsule to study the impact of probiotics on the gut microbiome.
Atmo Biosciences beat 10 other contenders to win the Early Stage Investment Forum (ESIF) at AusBiotech 2019, held at the Melbourne Convention Centre last week.
Former Cochlear Chief Executive Officer Dr. Chris Roberts AO has been appointed as a Non-Executive Director to the Board of Atmo Biosciences, a digital health business commercializing a world-first ingestible gas-sensing capsule for gut health.
Two human trials of Atmo Biosciences’ ingestible gas-sensing capsule have begun.
The first trial is being conducted at Monash University and the Alfred Hospital in Melbourne, Australia, in collaboration with the research team led by Professor Peter Gibson and Professor Jane Muir.
Atmo Biosciences exhibited at Australian Gastroenterology Week Conference in Adelaide thanks to the generous support of C.R. Kennedy.
Atmo Biosciences has signed a licensing deal with RMIT University securing the exclusive worldwide rights to commercialize a ground-breaking ingestible gas-sensing capsule.
Findings from the first human trials of a breakthrough gas-sensing swallowable capsule could revolutionize the way that gut disorders and diseases are prevented and diagnosed.